碘油为载体对原发性肝癌的导向综合治疗

Targeted Chemotherapy for Primary Liver Cancer with Lipiodol as a Carrier

以碘油（LPD）为载体对原发性肝癌实施导向综合治疗的实验和临床研究的初步结果．125I－LPD经肝动脉灌注后长期高选择性滞留在肝癌组织，其在大鼠肝癌的有效半衰期可达8．73±3．54天，125I－LPD与ADM和MMC的混合乳剂．对肝癌患者的导向综合治疗（内辐射，选择性化疗及栓塞）明显优于LPD的栓塞化疗．经患者肝动脉留量导管，反复多次治疗，可使肝癌组织的内辐射吸收剂量由单次给药的34±7．58rad，提高到94±12．30rad，患者的1年和2年生存率，分别提高至72％和42％．本组的研究结果初步表明，125I－LPD为主的导向综合治疗，是一种安全，有效的治疗肝癌的新方法．

The paper reports the results of experimental and clinical studies of targeted chemotherapy for primary liver cancer (PLC) with Lipiodol (LPD) as a carrier. 125I-LPD was concentrated in the tumours after it was injected through the hepatic artery.The average effective half life of 125I-LPD in tumours was 8. 73± 3. 54 days in rats. The results of targeted chemotherapy with 125ILPD mixed with ADM and MMC were obviously better than that of embolized chemotherapy with LPD mixed with ADM and MMC in patients suffered from PLC. The radiation dore of 125I to tumours was raised from 34±7. 580 rad to 94± 12. 30 rad along with repeated injection of 125I-LPD in the Patients. The suvival rates at Lyear and 2-yea were 72 % and 42% respectively. The abov results show the new method for the treatment of PLC is effective and safe.